Bluejay Advances Symphony IL-6 Sepsis Diagnostic Program

Bluejay Diagnostics ( (BJDX) ) has shared an announcement.

On March 12, 2026, Bluejay Diagnostics announced that an abstract on its Symphony IL-6 Test was accepted for presentation at the 2026 Society of Academic Emergency Medicine Annual Meeting, to be held May 18–21 in Atlanta. The work will share data from SYMON-I, a multicenter pilot study examining how IL-6 levels in emergency department sepsis patients correlate with organ dysfunction measured by SOFA scores over the first three days of hospitalization.

Investigators reported that SYMON-I findings suggest emergency department IL-6 levels may be associated with subsequent organ dysfunction in sepsis and septic shock, adding to evidence that IL-6 could serve as an early biomarker in critically ill patients. Bluejay highlighted that SYMON-II, its pivotal validation study, is underway and is intended to underpin a future 510(k) submission, signaling progress toward potential FDA clearance and reinforcing the strategic importance of Symphony IL-6 within sepsis diagnostics.

The most recent analyst rating on (BJDX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Bluejay Diagnostics stock, see the BJDX Stock Forecast page.

Spark’s Take on BJDX Stock

According to Spark, TipRanks’ AI Analyst, BJDX is a Neutral.

The score is held down primarily by very weak financial performance (minimal revenue, ongoing losses, and sustained cash burn) and a bearish technical setup below key moving averages. Positive corporate developments in clinical progress and manufacturing readiness provide some offset, but they do not yet translate into proven revenue traction or profitability.

To see Spark’s full report on BJDX stock, click here.

More about Bluejay Diagnostics

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on rapid near‑patient testing for critical care conditions, centered on its Symphony System for sepsis triage and monitoring. Its lead product candidate, the Symphony IL-6 Test, is designed to deliver IL-6 biomarker results in about 20 minutes to support earlier, more informed treatment decisions, but the system has not yet received U.S. regulatory clearance.

The company’s market focus is on emergency and intensive care settings where faster sepsis risk stratification and monitoring could improve outcomes and resource utilization. Bluejay aims to use data from its SYMON clinical study program to support regulatory submissions and position Symphony as a cost-effective tool in managing critically ill patients.

Average Trading Volume: 237,765

Technical Sentiment Signal: Sell

Current Market Cap: $1.97M

Find detailed analytics on BJDX stock on TipRanks’ Stock Analysis page.